kctd15l Antibody

What is KCTD15 and why is it a target of interest for antibody development?

KCTD15 (potassium channel tetramerisation domain containing 15) is a protein involved in various biological processes including neural crest formation during embryonic development and signaling pathway regulation. It contains a BTB (POZ) domain and has been implicated in multiple cellular functions . Research interest in KCTD15 has grown due to its:

• Role in inhibiting AP-2 transcriptional activity through interaction with its activation domain

• Function as a negative regulator of neural crest formation via Wnt/β-catenin signaling pathway repression

• Emerging evidence as an anti-tumor factor in colorectal cancer

• Association with various diseases including obesity, neurological disorders, and cancer

The development of specific antibodies against KCTD15 enables researchers to study its expression patterns, protein interactions, and functional roles in different biological contexts .

What applications are validated for KCTD15 antibodies?

KCTD15 antibodies have been validated for multiple laboratory applications with specific optimization parameters:

Note: Optimal working dilutions should be determined experimentally for each specific application and sample type .

How do I determine the specificity of my KCTD15 antibody?

Confirming antibody specificity is crucial for reliable experimental results. For KCTD15 antibodies, validation approaches include:

• Western blot verification: The predicted molecular weight of KCTD15 is 31-32 kDa, though it may appear at 26 kDa in some systems. Validate by comparing with positive control tissues like brain, spleen, or HEK-293 cells .

• Knockdown/knockout controls: Use KCTD15 knockdown or knockout samples as negative controls. Published studies have used this approach to confirm antibody specificity .

• Immunoprecipitation followed by mass spectrometry: This can confirm that the antibody is pulling down the intended target.

• Cross-reactivity testing: Test reactivity across species if working with non-human samples. Most commercial KCTD15 antibodies react with human, mouse, and rat samples .

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to block specific binding sites. Signal reduction indicates specificity .

What are the optimal conditions for Western blot detection of KCTD15?

For successful Western blot detection of KCTD15, follow these optimized protocols:

• Sample preparation:

  • For cell lines: Use RIPA buffer with protease inhibitors

  • For tissues: Homogenize in RIPA buffer, sonicate briefly, and centrifuge at 14,000×g for 15 minutes

  • Load 10-35 μg of total protein per lane

• Electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels

  • Transfer to nitrocellulose or PVDF membranes at 100V for 1 hour or 30V overnight

• Blocking and antibody incubation:

  • Block with 5% non-fat milk in TBST for 1 hour at room temperature

  • Primary antibody dilution: 1:500-1:1000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Secondary antibody: Anti-rabbit or anti-mouse HRP-conjugated (depending on primary antibody host) at 1:5000-1:10000

• Detection and troubleshooting:

  • Use ECL detection system

  • Expected band size: 31-32 kDa (calculated), but may appear at 26 kDa in some systems

  • If multiple bands appear, optimize antibody concentration or try different lysis buffers

  • Positive controls: HEK-293 cells, brain tissue, C6 cells

How should I optimize immunohistochemistry protocols for KCTD15 detection in different tissue types?

Optimization strategies for KCTD15 immunohistochemistry include:

• Fixation and embedding:

  • Optimal fixation: 10% neutral buffered formalin for 24-48 hours

  • Process and embed in paraffin using standard protocols

• Antigen retrieval methods:

  • Primary recommendation: TE buffer pH 9.0 (high pH)

  • Alternative: Citrate buffer pH 6.0 (if high pH retrieval yields high background)

  • Heat-induced epitope retrieval: 95-98°C for 15-20 minutes

• Antibody dilution and incubation:

  • Start with 1:100 dilution (range: 1:50-1:500)

  • Incubate at 4°C overnight or 1-2 hours at room temperature

  • Use appropriate negative controls (isotype control or secondary antibody only)

• Detection systems:

  • HRP-polymer detection systems yield cleaner results than avidin-biotin methods

  • Counterstain with hematoxylin for nuclear visualization

• Tissue-specific considerations:

  • Spleen tissues show robust KCTD15 expression

  • Smooth muscle tissues require more extensive antigen retrieval

  • Brain tissues may require longer primary antibody incubation

What methods are recommended for measuring KCTD15 levels in blood cells using flow cytometry?

For flow cytometric analysis of KCTD15 in blood cells:

• Sample preparation:

  • Use freshly collected peripheral blood or isolated mononuclear cells

  • For fixed samples, use PerFix Expose kit for optimal intracellular staining

• Surface marker staining:

  • Include CD45 (pan-leukocyte marker) and CD14 (monocyte marker) for population identification

  • Stain with fluorochrome-conjugated antibodies for 15-30 minutes at room temperature

• Permeabilization and fixation:

  • Fix cells with 2-4% paraformaldehyde for 10-15 minutes

  • Permeabilize with 0.1% saponin or 0.1% Triton X-100

• Intracellular KCTD15 staining:

  • Incubate with KCTD15 antibody (concentration determined by titration)

  • Use appropriate isotype control

  • Apply fluorochrome-conjugated secondary antibody if primary is unconjugated

• Gating strategy:

  • Select single-cell events on FSC-H vs. FSC-A

  • Identify live cells on FSC-A vs. SSC-A

  • Use CD45 vs. SSC to differentiate lymphocytes (CD45bright/SSClow), monocytes (CD45dim/SSCdim/CD14+), and granulocytes (CD45dim/SSCbright/CD14-)

  • Measure KCTD15 expression in each population

This approach has been validated for detecting differential KCTD15 expression between normal blood cells and leukemic cells .

How can I investigate KCTD15's role in the inhibition of AP-2 transcriptional activity?

To study KCTD15's inhibition of AP-2 transcriptional activity:

• Reporter assay system:

  • Use the AP2-Luc reporter construct containing three copies of the AP-2 consensus binding site controlling luciferase expression

  • Co-transfect with AP-2α expression construct and varying amounts of KCTD15 expression construct

  • Measure luciferase activity 24-48 hours post-transfection

  • Include appropriate controls (empty vector, mutant constructs)

• Protein-protein interaction analysis:

  • Co-immunoprecipitation: Immunoprecipitate AP-2α and blot for KCTD15 or vice versa

  • Focus on the activation domain of AP-2α, as KCTD15 specifically binds to this region

  • Test the P59A mutation in AP-2α, which renders it insensitive to KCTD15 inhibition

• Chromatin immunoprecipitation (ChIP):

  • Perform ChIP with AP-2α antibody in the presence/absence of KCTD15

  • Target known AP-2 binding sites in genes like MSX1, PAX3, FOXD3, and SNAI2

  • KCTD15 does not prevent AP-2α binding to chromatin but inhibits its transcriptional activation function

• Domain mapping:

  • Generate deletion constructs of both proteins to map the interaction domains

  • The BTB domain of KCTD15 may be crucial for protein-protein interactions

This approach has revealed that KCTD15 is a highly effective inhibitor of AP-2 activity and acts by binding specifically to the activation domain of AP-2α .

What techniques can be used to study KCTD15's potential anti-tumor effects in cancer cells?

To investigate KCTD15's anti-tumor properties:

• Expression analysis in tumor vs. normal tissues:

  • Compare KCTD15 expression by qRT-PCR, Western blot, and IHC between tumor and adjacent normal tissues

  • Correlate expression levels with clinical parameters and patient outcomes

• Functional studies in cancer cell lines:

  • Overexpression: Use tetracycline-inducible expression vectors for controlled KCTD15 expression

  • Knockdown: Apply siRNA or shRNA techniques for KCTD15 silencing

  • Measure effects on:

    • Cell viability (MTT assay)

    • Proliferation (EdU incorporation, colony formation)

    • Apoptosis (Annexin V-FITC/PI staining, caspase activation)

    • Cell cycle progression (PI staining, cyclin expression)

• Molecular mechanism investigation:

  • Analyze p53 acetylation status at Lys373 and Lys382

  • Measure HDAC1 protein levels and activity

  • Assess stability of p53 protein through cycloheximide chase assays

  • Conduct co-immunoprecipitation studies to identify protein interaction partners

• In vivo tumor models:

  • Establish xenograft models using KCTD15-modulated cancer cells

  • Monitor tumor growth, apoptosis (TUNEL staining), and protein expression (IHC)

  • Evaluate treatment response in KCTD15-high vs. KCTD15-low tumors

Recent research has shown that KCTD15 overexpression decreases cell viability, inhibits proliferation, and increases apoptosis in colorectal cancer cells through mechanisms involving p53 stabilization and HDAC1 regulation .

How does KCTD15 interact with the NF-κB signaling pathway in leukemia, and what techniques can be used to study this?

To investigate KCTD15's role in NF-κB signaling in leukemia:

• Expression correlation analysis:

  • Perform comparative transcriptome analysis between leukemia patients and healthy subjects

  • Cluster differentially expressed genes using pathway analysis tools (e.g., Ingenuity Pathway Analysis)

  • Focus on NF-κB activation pathway components

• Protein phosphorylation studies:

  • Measure phosphorylation status of key NF-κB pathway proteins (p65/RelA, IκB-α, IKK-β) by Western blot

  • Compare between KCTD15-modulated conditions (overexpression or knockdown)

  • Use phospho-specific antibodies to detect activation states

• Protein-protein interaction analysis:

  • Co-immunoprecipitation: Immunoprecipitate IKK-β and blot for KCTD15

  • Proximity ligation assay (PLA): Detect endogenous IKK-β/KCTD15 interactions by flow cytometry

  • BiFC (Bimolecular Fluorescence Complementation) to visualize interactions in living cells

• Functional outcome assessment:

  • NF-κB reporter assays to measure transcriptional activity

  • qRT-PCR for NF-κB target genes

  • Cell viability and apoptosis assays in leukemia cell lines

Research has shown that KCTD15 physically interacts with IKK-β in leukemia cells, potentially regulating NF-κB signaling. This interaction may contribute to KCTD15's role in leukemia cell survival and proliferation .

What are common issues with KCTD15 antibody detection and how can they be resolved?

Common challenges and solutions when working with KCTD15 antibodies:

Remember that KCTD15 has been reported at both 32 kDa (calculated) and 26 kDa (observed) molecular weights in different systems, so band sizes may vary .

How can I validate functional assays involving KCTD15 and ensure reproducibility?

For robust functional assays involving KCTD15:

• Expression modulation validation:

  • Confirm overexpression or knockdown efficiency by both qRT-PCR and Western blot

  • Use at least two different siRNA/shRNA sequences for knockdown studies

  • Include rescue experiments (re-expressing KCTD15 in knockdown cells) to confirm specificity

• Controls and replicates:

  • Include appropriate positive and negative controls in each experiment

  • Perform at least three biological replicates and technical replicates

  • Analyze data using appropriate statistical methods

• Multi-method confirmation:

  • Verify key findings using complementary approaches (e.g., confirm proliferation effects with both EdU incorporation and colony formation)

  • Use multiple cell lines to ensure findings aren't cell-type specific

  • Validate in vivo findings with clinical samples when possible

• Pathway validation:

  • For mechanistic studies (e.g., KCTD15's effect on AP-2 or NF-κB signaling), use both gain- and loss-of-function approaches

  • Include pathway inhibitors or activators as controls

  • Test multiple downstream targets to confirm pathway engagement

• Documentation and reporting:

  • Maintain detailed records of antibody lots, cell passage numbers, and experimental conditions

  • Report all essential methodological details, including antibody catalog numbers and dilutions

  • Share raw data when publishing to enhance reproducibility

These practices have been successfully implemented in studies examining KCTD15's role in neural crest development, cancer progression, and signaling pathways .

What considerations should be taken into account when analyzing contradictory data about KCTD15 function across different cellular contexts?

When reconciling contradictory findings about KCTD15 function:

• Cellular context differences:

  • KCTD15 may function differently in embryonic versus adult tissues

  • Cancer cells may show altered KCTD15 function compared to normal cells

  • Tissue-specific interaction partners may modify KCTD15 activity

• Methodological variations:

  • Different antibodies may recognize distinct epitopes or isoforms

  • Expression levels in overexpression studies may not reflect physiological conditions

  • Acute versus chronic modulation of KCTD15 may yield different results

• Molecular pathway cross-talk:

  • KCTD15 interacts with multiple pathways (AP-2, Wnt/β-catenin, NF-κB, Hedgehog)

  • Dominant pathways may vary between cell types

  • Consider the activation state of interacting pathways in each experimental system

• Data analysis approaches:

  • Perform meta-analysis across multiple studies when possible

  • Look for patterns in contradictions (e.g., consistent in cancer vs. normal cells)

  • Consider dose-dependent effects and threshold phenomena

• Resolution strategies:

  • Design experiments that directly compare conditions in the same system

  • Test whether contradictions result from different splice variants or post-translational modifications

  • Investigate temporal dynamics of KCTD15 activity

Recent research shows that KCTD15 functions as an anti-tumor factor in colorectal cancer but has distinct roles in neural development and leukemia, highlighting the importance of cellular context in determining its function .

What are the latest findings regarding KCTD15's role in disease pathways beyond neural development?

Recent research has expanded our understanding of KCTD15's involvement in various diseases:

• Cancer biology:

  • Functions as an anti-tumor factor in colorectal cancer through p53 stabilization

  • Decreases HDAC1 protein expression and increases p53 acetylation at Lys373 and Lys382

  • Shows decreased expression in colorectal cancer tissues compared to adjacent normal tissues

  • May serve as a prognostic biomarker in early-stage colorectal cancer

• Hematological disorders:

  • Shows altered expression in B-cell acute lymphoblastic leukemia (B-ALL)

  • Physically interacts with IKK-β in leukemia cells

  • Modulates NF-κB signaling pathway activation

  • Displays higher expression in acute myeloid leukemia cells compared to normal peripheral blood cells

• Metabolic disorders:

  • Associated with obesity and related metabolic conditions

  • Implicated in asthma, cardiovascular diseases, and diabetes

  • May influence insulin resistance pathways

  • Genetic variations in KCTD15 have been linked to birth weight variations

• Medulloblastoma:

  • Inhibits the Hedgehog signaling pathway in medulloblastoma cells

  • Decreases Gli1-responsive luciferase reporter activity

  • Reduces HDAC1 protein levels and increases Gli1 acetylation

  • Expression is reduced in Sonic Hedgehog (SHH) subgroup medulloblastomas

These findings suggest that KCTD15 functions as a multifaceted regulator across diverse physiological and pathological contexts.

How can advanced imaging techniques be combined with KCTD15 antibodies to study its subcellular localization and dynamics?

Advanced imaging approaches for studying KCTD15:

• Super-resolution microscopy:

  • Structured Illumination Microscopy (SIM) can resolve KCTD15 localization with 120 nm resolution

  • Stochastic Optical Reconstruction Microscopy (STORM) or Photoactivated Localization Microscopy (PALM) enable single-molecule localization with 20-30 nm resolution

  • Stimulated Emission Depletion (STED) microscopy can reveal fine details of KCTD15 distribution

• Live-cell imaging techniques:

  • CRISPR-Cas9 knock-in of fluorescent tags for endogenous KCTD15 visualization

  • Photoactivatable or photoconvertible fluorescent protein fusions to track KCTD15 movement

  • Fluorescence Recovery After Photobleaching (FRAP) to measure KCTD15 mobility and binding dynamics

• Proximity-based methods:

  • Förster Resonance Energy Transfer (FRET) to study KCTD15 interactions with binding partners

  • Bimolecular Fluorescence Complementation (BiFC) to visualize protein-protein interactions in live cells

  • Proximity Ligation Assay (PLA) to detect endogenous protein interactions with high sensitivity

• Correlative microscopy approaches:

  • Correlative Light and Electron Microscopy (CLEM) to match fluorescence localization with ultrastructural context

  • Expansion microscopy combined with immunofluorescence for physical magnification of structures

  • Sequential imaging with orthogonal labeling strategies

• Image analysis considerations:

  • Machine learning approaches for automatic segmentation and quantification

  • 3D reconstruction for volumetric analysis

  • Colocalization analysis with nuclear, cytoplasmic, or organelle markers

These advanced techniques can help resolve the predominantly cytoplasmic localization of KCTD15 and its potential nuclear translocation under specific conditions .

What are the predicted molecular interactions between KCTD15 and other proteins based on structural biology data, and how can these be experimentally validated?

Predicted molecular interactions and validation approaches:

• Structural predictions and domains:

  • KCTD15 contains a BTB (POZ) domain implicated in protein-protein interactions

  • Molecular modeling suggests potential interaction surfaces within this domain

  • Homology with other KCTD family members indicates possible shared interaction partners

  • Predicted to form oligomeric structures (tetramers) through the BTB domain

• Known interaction partners:

  • AP-2α: KCTD15 binds specifically to the activation domain of AP-2α

  • IKK-β: Co-immunoprecipitation and PLA studies confirm interaction

  • Potential interaction with Cullin-3 (Cul3) to form E3 ubiquitin ligase complexes

  • HDAC1: Functional studies suggest interaction leading to HDAC1 degradation

• Validation methodologies:

  • Structural biology approaches:

    • X-ray crystallography of KCTD15 alone or in complex with partners

    • Cryo-EM analysis of larger protein complexes

    • NMR spectroscopy for dynamic interaction studies

  • Biochemical techniques:

    • Pull-down assays with recombinant proteins

    • Surface Plasmon Resonance (SPR) or Bio-Layer Interferometry (BLI) for binding kinetics

    • Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) to map interaction surfaces

  • Cellular approaches:

    • Mutational analysis targeting specific residues (e.g., P59A mutation in AP-2α disrupts KCTD15 binding)

    • FRET/BRET assays for live-cell interaction studies

    • Protein-fragment complementation assays

• Predicted novel interactions:

  • Components of the Wnt/β-catenin pathway based on functional inhibition

  • Ubiquitin-proteasome system proteins given the role of KCTD proteins as adaptors for E3 ligases

  • Transcriptional regulators beyond AP-2α, potentially including p53-related factors

Experimental validation has confirmed KCTD15's interaction with AP-2α's activation domain, with mutation of a specific proline residue (P59A) rendering AP-2α insensitive to KCTD15 inhibition .

How might single-cell analysis techniques advance our understanding of KCTD15 expression heterogeneity in complex tissues and disease states?

Single-cell approaches for studying KCTD15 heterogeneity:

• Single-cell RNA sequencing (scRNA-seq):

  • Profile KCTD15 expression across thousands of individual cells

  • Identify cell populations with high or low KCTD15 expression

  • Correlate KCTD15 expression with cell states and other markers

  • Map developmental trajectories in embryonic tissues where KCTD15 regulates neural crest formation

• Single-cell proteomics:

  • Mass cytometry (CyTOF) incorporating KCTD15 antibodies for protein-level quantification

  • SCoPE-MS (Single Cell ProtEomics by Mass Spectrometry) to detect KCTD15 and interacting partners

  • Identify post-translational modifications at single-cell resolution

• Spatial transcriptomics and proteomics:

  • Visium spatial gene expression platform to map KCTD15 expression in tissue context

  • Multiplexed ion beam imaging (MIBI) or Imaging Mass Cytometry (IMC) for spatial protein analysis

  • CODEX (CO-Detection by indEXing) for highly multiplexed protein imaging

• Integration with functional data:

  • Patch-seq to correlate KCTD15 expression with electrophysiological properties in neurons

  • Live-cell imaging combined with single-cell sequencing to link dynamics to expression profiles

  • CRISPR screens with single-cell readouts to identify functional partners

• Computational approaches:

  • Trajectory inference to map KCTD15 expression changes during cellular differentiation

  • Gene regulatory network inference to position KCTD15 in cellular decision-making

  • Integration of multi-omics data at single-cell resolution

These approaches could reveal previously unappreciated heterogeneity in KCTD15 expression and function across tissues and disease states, particularly in cancer where intratumoral heterogeneity is a challenge to therapy .

What emerging high-throughput methods could accelerate the discovery of compounds that modulate KCTD15 activity?

High-throughput approaches for identifying KCTD15 modulators:

• Screening platforms:

  • Cell-based reporter assays using KCTD15-responsive elements (e.g., AP-2 response elements coupled to luciferase)

  • Phenotypic screens measuring proliferation or apoptosis in KCTD15-dependent systems

  • Protein-protein interaction screens (split luciferase assays) targeting KCTD15-AP-2α interaction

  • FRET/BRET-based screening for compounds that disrupt or enhance protein interactions

• CRISPR-based approaches:

  • CRISPR activation (CRISPRa) or interference (CRISPRi) screens to identify synthetic lethal interactions

  • Perturb-seq combining CRISPR perturbation with single-cell transcriptomics

  • Base editor or prime editor screens to systematically test effects of KCTD15 mutations

• Advanced biochemical methods:

  • Thermal shift assays to identify compounds binding KCTD15

  • Hydrogen-Deuterium Exchange Mass Spectrometry (HDX-MS) to map structural changes upon compound binding

  • MicroScale Thermophoresis (MST) for measuring binding affinities in high-throughput format

• Computational approaches:

  • Structure-based virtual screening using homology models of KCTD15

  • Machine learning models trained on known protein-protein interaction modulators

  • Network-based drug repurposing approaches targeting KCTD15-related pathways

• Target validation technologies:

  • Targeted protein degradation approaches (PROTACs) specific for KCTD15

  • Rapidly inducible protein expression/degradation systems for temporal control

  • In vivo gene editing for preclinical model development

These methods could lead to the development of tool compounds or potential therapeutics targeting KCTD15 activity in diseases where it plays a role, such as colorectal cancer where increasing KCTD15 activity might be beneficial, or in contexts where inhibiting its function might be therapeutic .

How can systems biology approaches integrate KCTD15 into larger signaling networks to better understand its context-dependent functions?

Systems biology strategies for understanding KCTD15 network integration:

• Multi-omics data integration:

  • Combine transcriptomics, proteomics, and metabolomics data from KCTD15-modulated systems

  • Generate correlation networks to identify molecules whose levels change with KCTD15

  • Apply weighted gene co-expression network analysis (WGCNA) to identify KCTD15-associated modules

  • Integrate epigenomics data to understand regulatory mechanisms

• Pathway and network analysis:

  • Use tools like Ingenuity Pathway Analysis, KEGG, or STRING to place KCTD15 in known pathways

  • Apply network propagation algorithms to predict additional connections

  • Perform network perturbation analysis using data from KCTD15 manipulation experiments

  • Network comparison across different cellular contexts to identify context-specific interactions

• Mathematical modeling approaches:

  • Develop ordinary differential equation (ODE) models of KCTD15-involved pathways

  • Create Boolean network models to predict qualitative system behavior

  • Apply logic-based modeling to integrate diverse data types

  • Sensitivity analysis to identify key parameters controlling KCTD15 function

• Machine learning integration:

  • Train predictive models on multi-omics data to identify contexts where KCTD15 is functional

  • Apply feature importance methods to rank factors influencing KCTD15 activity

  • Use transfer learning to translate findings between different cellular systems

  • Develop interpretable AI models that can generate testable hypotheses

• Experimental validation strategies:

  • Multiplexed CRISPR perturbation to test predicted network interactions

  • Orthogonal validation across multiple model systems

  • Temporal analysis to capture dynamic aspects of network behavior

  • Targeted biochemical studies to confirm direct interactions